Why the study?
Differences in immature platelet fraction levels across acute coronary syndrome subtypes (STEMI vs NSTEMI/UAP) were assessed alongside traditional cardiac biomarkers.
Does the Immature Platelet Fraction (IPF) level differ between STEMI and NSTEMI/UAP in patients with Acute Coronary Syndrome?
Does the Immature Platelet Fraction (IPF) level differ between STEMI and NSTEMI/UAP in patients with Acute Coronary Syndrome?
Answers are grounded in this paper and cite their sources.
Immature Platelet Fraction (IPF) levels are significantly higher in patients with STEMI compared to those with NSTEMI/UAP, suggesting its potential utility as a biomarker for differentiating ACS severity.
Background: Acute Coronary Syndrome (ACS) is a major cardiovascular problem because it causes high hospital admissions and mortality rates. Acute Coronary Syndrome is divided into 3 (three), namely: unstable angina pectoris (UAP), myocardial infarction without ST segment elevation (NSTEMI), and myocardial infarction with ST segment elevation (STEMI). In addition to changes in biomarkers of heart injury, the platelet index (IPF = immature platelet fraction) will also change the level difference between STEMI with NSTEMI/UAP. Objective: To determine the differences in IPF levels of ACS patients with STEMI and NSTEMI/UAP Method: Observational analytic with cross sectional approach. The subjects of this study were 80 patients who came to the emergency installation of integrated heart center Emergency Room Haji Adam Malik Hospital Medan from May 2019 to September 2019 and was diagnosed with ACS (STEMI or NSTEMI/UAP). The sample in the study was the patient's venous blood and put it in an EDTA tube, then immediately checked the IPF value/level using the automatic hematology analyzer. Patients with heart failure or patients with thrombocytopenia were not included in this study. Results: In this study, the demographic characteristics of the ACS patients based on gender were male 77.5% STEMI and 87.5% NSTEMI/UAP while women 22.5% STEMI and 12.5% NSTEMI/UAP. The results of the STEMI patient's IPF levels Compared with NSTEMI/UAP, the median is 6.2 (3.5-16.8) VS 2.9 (0.7-12) with a p-value of 0.0001. Conclusion: The characteristics of ACS patients based on the results of sex were that there were more men with NSTEMI/UAP than those with STEMI. There was a significant difference in the IPF levels of STEMI with NSTEMI/UAP.
No takes yet. Share an insight, caveat, or question.
Sari et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: